Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.01
-22.4%		$0.03
$0.01
▼
$6.66
$176K0.06217,803 shs217,623 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
+60.0%		$0.00
$0.00
▼
$0.05
$441K0.11253,159 shs21,117 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.02
$0.01
$0.00
▼
$0.07
$79K1.414,799 shs250 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+70.80%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+26.26%-21.38%-49.39%-86.28%-99.72%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+25.00%-37.50%-50.00%-90.00%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%0.00%+18.11%+18.11%-60.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.01
-22.4%		$0.03
$0.01
▼
$6.66
$176K0.06217,803 shs217,623 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
+60.0%		$0.00
$0.00
▼
$0.05
$441K0.11253,159 shs21,117 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.02
$0.01
$0.00
▼
$0.07
$79K1.414,799 shs250 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+70.80%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+26.26%-21.38%-49.39%-86.28%-99.72%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+25.00%-37.50%-50.00%-90.00%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%0.00%+18.11%+18.11%-60.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.00
SellN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.03N/AN/A$2.46 per share0.00
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.01N/AN/AN/A∞
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$2.25N/AN/AN/A-825.01%-482.05%-88.90%11/5/2026 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A11/6/2026 (Estimated)
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$5.31N/AN/AN/AN/A-248.33%-132.73%11/10/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
61.14 million1.10 millionNo Data
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13018.12 million5.44 millionNo Data
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
949551.28 million536.95 millionNo Data
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable

Recent News About These Companies

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs
April 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/antibody-drug-conjugates-adc-market-095100337.html
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
January 18, 2026  |  defenseworld.netD
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...
July 16, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2982429/vincerx-pharma-inc-announces-additional-adjournment-of-special-meeting--urges-stockholders-to-vote-for-approval-of-dissolution-proposal--vinc-stock-news
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
July 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/16/3116827/0/en/Vincerx-Pharma-Inc-Announces-Additional-Adjournment-of-Special-Meeting-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal.html
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times
July 9, 2025  |  manilatimes.netM
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar
July 9, 2025  |  morningstar.comM
Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance
July 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VINC/financials/
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
July 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/07/3111291/0/en/Vincerx-Pharma-Inc-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal-and-Announces-Potential-Range-for-Distributions-to-Stockholders.html
Vincerx Pharma, Inc. (VINC) - Yahoo Finance
July 2, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VINC/press-releases/
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
June 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/18/3101905/0/en/Vincerx-Pharma-Inc-Announces-Adjournment-of-Special-Meeting-Will-Reconvene-Meeting-on-July-16-2025-to-Secure-Votes-Needed-to-Approve-Dissolution-Proposal.html
Vincerx Pharma announces plan to delist from Nasdaq
April 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-plan-to-delist-from-nasdaq-1034597516
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vincerx-pharma-inc-announces-intent-204500865.html
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/17/3063864/0/en/vincerx-pharma-inc-announces-intent-to-delist-from-nasdaq-and-deregister-with-the-sec.html
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down
April 9, 2025  |  fiercebiotech.comF
Vincerx terminates letter of intent with Global Digital, initiates wind down
April 9, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-terminates-letter-of-intent-with-global-digital-initiates-wind-down-1034562524
Financially struggling drugmaker's potential rescue falls apart. It now will wind down
April 9, 2025  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2025/04/08/cancer-vincerx-pharma-qumulusai-merger-fails.html
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
April 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/08/3057992/0/en/Vincerx-Pharma-Announces-Termination-of-Letter-of-Intent-and-Board-Authorization-to-Pursue-Wind-Down-Activities.html
Vincerx Pharma announces non-binding LOI for Qumulus AI combination
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-non-binding-loi-for-qumulus-ai-combination-1034489795
Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
March 18, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64858522-vincerx-pharma-inc-vincerx-pharma-announces-non-binding-letter-of-intent-for-business-combination-with-qumulusai-399.htm
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis
March 18, 2025  |  fiercebiotech.comF

New MarketBeat Followers Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 09/23/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.0097 0.00 (-22.40%)
As of 02:18 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0008 +0.00 (+60.00%)
As of 03:57 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.02 0.00 (0.00%)
As of 09/23/2026 09:30 AM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas